Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model

Abstract

Severe influenza complications are often caused by Streptococcus pneumoniae infection, which presents the most common cause of community-acquired pneumonia. We evaluated in a mouse model an associated virus-bacterial vaccine based on seasonal live influenza vaccines (LAIV) and S. pneumoniae chimeric protein comprising flagellin (PSPF). Intranasal immunization of mice with a complex of trivalent LAIV and PSPF caused an increased release of early cytokines in the lungs of mice. The immunogenicity of LAIV and PSPF in the associated vaccine composition was sometimes decreased compared to each vaccine preparation alone. Nevertheless, only vaccination of mice with LAIV+PSPF significantly reduced lethality and the bacterial load in the lungs in a model of post-influenza bacterial pneumonia. The study of the interactions of influenza viruses with bacterial peptides is important during the development of associated virus-bacterial vaccines intended for the prevention of severe post-influenza bacterial complications.

Mucosal Vaccines against Bacterial and Viral Pathogens

“…Чужеродные, в том числе вакцинные, антиге ны проходят путь от ротовой полости до просвета кишечника, постепенно проникая через эпители альный барьер слизистой оболочки к лимфоидной ткани с помощью дендритных клеток и макрофа гов, а в кишечнике преимущественно посредством специализированных эпителиальных Мклеток [13]. После прохождения эпителиального барьера антигены встречаются с компактно расположен ными специализированными клетками иммунной системы (дендритными клетками, макрофагами, Тлимфоцитами разных классов и Влимфоцитами).…”